Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Molecular & Cellular Proteomics : MCP|June 29, 2019
Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer PatientsAndrei P Drabovich, Punit Saraon, Mikalai Drabovich, et al.
Biochimica Et Biophysica Acta. Biomembranes|March 4, 2020
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticinMauricio Arias, Evan F Haney, Ashley L Hilchie, et al.
Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire|February 7, 2017
Anticancer activities of bovine and human lactoferricin-derived peptidesMauricio Arias, Ashley L Hilchie, Evan F Haney, et al.
Urologic Oncology|June 14, 2011
Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomyPhillip M Pierorazio, Brian M Lin, Jeffrey K Mullins, et al.
Urology|October 8, 2013
Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomyDeborah R Kaye, M Eric Hyndman, Robert L Segal, et al.
Life Science Alliance|December 30, 2020
Tissue-selective alternate promoters guide NLRP6 expressionNathan A Bracey, Jaye M Platnich, Arthur Lau, et al.
JAMA Network Open|August 6, 2021
Evaluation of the Implementation of Multiple Enhanced Recovery After Surgery Pathways Across a Provincial Health Care System in Alberta, CanadaGregg Nelson, Xiaoming Wang, Alison Nelson, et al.
NPJ Digital Medicine|June 20, 2024
Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platformM Eric Hyndman, Robert J Paproski, Adam Kinnaird, et al.
NPJ Digital Medicine|April 17, 2026
Predicting clinically significant prostate cancer with or without digital rectal exam and MRI data using ClarityDX Prostate modelsRobert J Paproski, Adam Kinnaird, M Eric Hyndman, et al.
Urologic Oncology|June 7, 2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCGRyan L Steinberg, Vignesh T Packiam, Lewis J Thomas, et al.
Pageof 3